Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT, GC | February 28, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 191,899 |
Reported balance
After 2025-02-28 transaction · row 1
1 source rowRow 1 · 2025-02-28 · Tax withholding · Disposed 8,382 · Balance 191,899 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 5, 2025 00:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,382 | $135.87 | $1,138,862.34 |
DisclosureSEC source: 0001415889-25-006738 · form4-03052025_120336.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT, GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,899 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 57,635 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005878 · form4-02272025_100208.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,635 Underlying: Common Shares · 57,635 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,211 on February 25, 2026, 19,212 on February 25, 2027, and 19,212 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005878 · form4-02272025_100208.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,281 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 58,428 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · derivative · entry 6 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 58,428 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 58,428 | $128.07 | $7,482,628.56 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,806 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.00 to $128.40, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 58,428 | $38.40 | $2,243,635.20 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 131,360 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,428 Underlying: Common shares · 131,360 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 131,360 | $128.35 | $16,859,675.06 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,806 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.90 to $128.81, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 131,360 | $38.40 | $5,044,224.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 157,421 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 157,421 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 150,271 | $116.98 | $17,578,701.58 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,806 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.68 to $117.64, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,901 | $118.15 | $697,203.15 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 335,077 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.68 to $118.59, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,249 | $118.81 | $148,393.69 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,978 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.68 to $118.92, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 157,421 | $47.00 | $7,398,787.00 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 853 | $118.50 | $101,080.50 |
DisclosureSEC source: 0001415889-24-006396 · form4-03042024_110352.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,806 Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,214 | $120.05 | $986,090.70 |
DisclosureSEC source: 0001415889-24-006396 · form4-03042024_110352.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,659 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 67,318 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005066 · form4-02232024_100225.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,318 Underlying: Common Shares · 67,318 shares Expires 2034-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,439 on February 21, 2025, 22,439 on February 21, 2026, and 22,440 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005066 · form4-02232024_100225.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,873 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,069 | $100.70 | $107,648.30 |
DisclosureSEC source: 0001415889-23-003889 · form4-03032023_120359.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,959 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,515 | $99.77 | $849,541.55 |
DisclosureSEC source: 0001415889-23-003889 · form4-03032023_120359.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,028 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 72,754 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003045 · form4-02222023_110256.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,754 Underlying: Common Shares · 72,754 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,251 on February 17, 2024, 24,251 on February 17, 2025, and 24,252 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003045 · form4-02222023_110256.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,543 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,450 | $118.17 | $171,347.95 |
DisclosureSEC source: 0001415889-22-002185 · form4-03022022_040327.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,095 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,878 | $122.41 | $1,209,165.98 |
DisclosureSEC source: 0001415889-22-002185 · form4-03022022_040327.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,545 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 95,000 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001729 · form4-02232022_040219.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Shares · 95,000 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 31,666 on February 18, 2023, 31,667 on February 18, 2024, and 31,667 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001729 · form4-02232022_040219.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,423 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,913 | $121.58 | $1,326,802.54 |
DisclosureSEC source: 0001415889-21-001195 · form4-03022021_030356.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,038 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 87,422 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000883 · form4-02232021_030230.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,422 Underlying: Common Shares · 87,422 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,140 on February 19, 2022, 29,141 on February 19, 2023, and 29,141 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000883 · form4-02232021_030230.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,951 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 95,600 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · derivative · entry 6 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,788 Underlying: Common Shares · 95,600 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 107,793 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 107,793 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,050 | $124.03 | $254,256.99 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,896 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 to $124.19, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 201,343 | $123.47 | $24,858,994.70 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,946 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.00 to $123.99, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 95,600 | $38.40 | $3,671,040.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 107,793 | $39.12 | $4,216,862.16 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,208 | $77.89 | $94,091.12 |
DisclosureSEC source: 0001179110-20-002896 · edgar.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,896 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 14,280 | $79.19 | $1,130,833.20 |
DisclosureSEC source: 0001179110-20-002896 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,104 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 130,298 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002278 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,298 Underlying: Common shares · 130,298 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 43,432 on February 21, 2021, 43,433 on February 21, 2022, and 43,433 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002278 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,384 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · derivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 165,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 165,000 | $85.00 | $14,025,000.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,010 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 165,000 | $34.94 | $5,765,100.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,246 | $78.00 | $175,188.00 |
DisclosureSEC source: 0001179110-19-003106 · edgar.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,010 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 14,843 | $77.23 | $1,146,324.89 |
DisclosureSEC source: 0001179110-19-003106 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,256 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 151,933 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002630 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,933 Underlying: Common shares · 151,933 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 50,644 on February 22, 2020, 50,644 on February 22, 2021, and 50,645 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002630 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,099 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,674 | $60.55 | $706,860.70 |
DisclosureSEC source: 0001179110-18-003297 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,114 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002526 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002526 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,788 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,600 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,600 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.